Manikat Richie, Ahmed Aijaz, Kim Donghee
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Gastroenterol Rep (Oxf). 2024 Jun 24;12:goae069. doi: 10.1093/gastro/goae069. eCollection 2024.
Chronic liver disease presents a significant global health burden, characterized by several etiologies, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), chronic hepatitis B virus infection, and chronic hepatitis C virus infection. This review explored current epidemiological trends and projections for each etiology, looking into their respective burdens and challenges. MASLD, formerly known as nonalcoholic fatty liver disease, is the most prevalent cause of chronic liver disease, and its global incidence and prevalence are steadily rising. ALD, fueled by increased alcohol consumption, is also on the rise, with concerning implications for future mortality rates. Chronic hepatitis B and C infections remain major public health concerns, particularly in specific regions of the world, necessitating concerted efforts for screening and treatment. The coronavirus disease 2019 (COVID-19) pandemic has impacted the epidemiology of chronic liver disease, exacerbating mortality rates and disrupting healthcare services. Mental health issues arising from the pandemic further complicate the treatment of chronic liver disease, making comprehensive healthcare strategies essential. Despite advancements in treatment, chronic liver disease continues to impose a substantial economic burden, emphasizing the importance of preventive measures and early intervention. In conclusion, ongoing surveillance and research efforts are crucial for understanding and addressing the evolving landscape of chronic liver disease. Comprehensive strategies that encompass prevention, screening, and treatment of its different etiologies are essential for mitigating its impact and improving patient outcomes.
慢性肝病是一项重大的全球健康负担,其病因多样,包括代谢功能障碍相关脂肪性肝病(MASLD)、酒精性肝病(ALD)、慢性乙型肝炎病毒感染和慢性丙型肝炎病毒感染。本综述探讨了每种病因的当前流行病学趋势和预测,研究了它们各自的负担和挑战。MASLD,前身为非酒精性脂肪性肝病,是慢性肝病最常见的病因,其全球发病率和患病率正在稳步上升。由于酒精消费增加,ALD也在上升,对未来死亡率有令人担忧的影响。慢性乙型和丙型肝炎感染仍然是主要的公共卫生问题,特别是在世界的特定地区,需要齐心协力进行筛查和治疗。2019年冠状病毒病(COVID-19)大流行影响了慢性肝病的流行病学,加剧了死亡率并扰乱了医疗服务。大流行引发的心理健康问题使慢性肝病的治疗更加复杂,因此全面的医疗保健策略至关重要。尽管治疗取得了进展,但慢性肝病继续带来巨大的经济负担,这凸显了预防措施和早期干预的重要性。总之,持续的监测和研究工作对于理解和应对慢性肝病不断变化的形势至关重要。涵盖其不同病因的预防、筛查和治疗的综合策略对于减轻其影响和改善患者结局至关重要。